Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023 Mar;167(1):30-35. doi: 10.5507/bp.2023.002. Epub 2023 Jan 25.

Abstract

Aim: The aim of this study was to identify whether NfL and CXCL13 cerebrospinal fluid (CSF) concentrations at diagnostic lumbar puncture can predict the course of multiple sclerosis (MS) in terms of relapses, higher expanded disability status scale (EDSS) and magnetic resonance imaging (MRI) activity.

Methods: We conducted a single-centre prospective observational cohort study at the MS center, University Hospital Ostrava, Czech Republic. CSF NfL (cNfL) and CXCL13 concentrations were examined (ELISA method) in patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) at the time of diagnostic lumbar puncture.

Results: A total of 44 patients with CIS or early RRMS were enrolled, 31 (70.5%) of whom were women. The median age at the time of CSF sampling was 31.21 years (IQR 25.43-39.32), and the follow-up period was 54.6 months (IQR 44.03-59.48). In the simple and multiple logistic regression models, CXCL13 levels did not predict relapses, MRI activity or EDSS > 2.5. Similarly, cNfL concentrations did not predict relapses or MRI activity in either model. In the multiple regression, higher cNfL levels were associated with reaching EDSS > 2.5 (odds ratio [OR] 1.002, 95% confidence interval [CI] 1.000 to 1.003).

Conclusions: Our data did not confirm cNfL and/or CXCL13 CSF levels were predictive factors for disease activity such as relapses and MRI activity at the time of diagnostic lumbar puncture in patients with RRMS. While cNfL CSF levels predicted higher disability only after adjustment for other known risk factors, elevated CSF CXCL13 did not predict higher disability at all.

Keywords: CXCL13; biomarkers; clinical course; multiple sclerosis; neurofilament light chain.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Biomarkers / cerebrospinal fluid
  • Chemokine CXCL13
  • Disease Progression
  • Female
  • Humans
  • Intermediate Filaments
  • Male
  • Multiple Sclerosis* / cerebrospinal fluid
  • Multiple Sclerosis* / diagnosis
  • Multiple Sclerosis, Relapsing-Remitting* / cerebrospinal fluid
  • Multiple Sclerosis, Relapsing-Remitting* / diagnostic imaging
  • Prospective Studies
  • Recurrence

Substances

  • Biomarkers
  • CXCL13 protein, human
  • Chemokine CXCL13